AP3225A - New combination between 4-{3-[CIS-hexahydrocyclopenta[C]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it - Google Patents

New combination between 4-{3-[CIS-hexahydrocyclopenta[C]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it

Info

Publication number
AP3225A
AP3225A AP2012006607A AP2012006607A AP3225A AP 3225 A AP3225 A AP 3225A AP 2012006607 A AP2012006607 A AP 2012006607A AP 2012006607 A AP2012006607 A AP 2012006607A AP 3225 A AP3225 A AP 3225A
Authority
AP
ARIPO
Prior art keywords
hexahydrocyclopenta
pyrrol
benzamide
propoxy
cis
Prior art date
Application number
AP2012006607A
Other languages
English (en)
Other versions
AP2012006607A0 (en
Inventor
Caryn Trocme-Thibierge
Aurore Sors
Annette Merdes
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47682151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of AP2012006607A0 publication Critical patent/AP2012006607A0/xx
Application granted granted Critical
Publication of AP3225A publication Critical patent/AP3225A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2012006607A 2011-12-09 2012-12-05 New combination between 4-{3-[CIS-hexahydrocyclopenta[C]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it AP3225A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1103777A FR2983732B1 (fr) 2011-12-09 2011-12-09 Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
AP2012006607A0 AP2012006607A0 (en) 2012-12-31
AP3225A true AP3225A (en) 2015-04-30

Family

ID=47682151

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006607A AP3225A (en) 2011-12-09 2012-12-05 New combination between 4-{3-[CIS-hexahydrocyclopenta[C]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it

Country Status (27)

Country Link
US (2) US8921409B2 (xx)
EP (1) EP2601942A1 (xx)
JP (1) JP5591310B2 (xx)
KR (1) KR101489670B1 (xx)
CN (1) CN103157111B (xx)
AP (1) AP3225A (xx)
AR (1) AR089112A1 (xx)
AU (1) AU2012258339A1 (xx)
BR (1) BR102012031031A2 (xx)
CA (1) CA2798549A1 (xx)
CL (1) CL2012003437A1 (xx)
CO (2) CO6660080A1 (xx)
CR (1) CR20120608A (xx)
EA (1) EA201201530A1 (xx)
EC (1) ECSP12012329A (xx)
FR (1) FR2983732B1 (xx)
GT (1) GT201200329A (xx)
MA (1) MA34867B1 (xx)
MD (1) MD4348B1 (xx)
MX (1) MX2012014184A (xx)
NI (1) NI201200178A (xx)
PE (1) PE20130813A1 (xx)
SG (1) SG191494A1 (xx)
TN (1) TN2012000563A1 (xx)
TW (1) TWI457123B (xx)
UY (1) UY34475A (xx)
WO (1) WO2013083887A1 (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3003466B1 (fr) * 2013-03-22 2015-08-07 Servier Lab Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques
KR101484405B1 (ko) * 2013-08-14 2015-01-19 서울대학교산학협력단 Ｎｉｎｊｕｒｉｎ１ 결핍 유래의 강박증 예방 또는 치료용 약학적 조성물
GB201509134D0 (en) * 2015-05-28 2015-07-15 Electrophoretics Ltd Biomolecules involved in Alzheimer's disease
JP7429942B2 (ja) * 2015-07-22 2024-02-09 アナベックス ライフ サイエンシズ コーポレイション テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60324788D1 (de) * 2002-05-31 2009-01-02 Lundbeck & Co As H Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
KR20070104480A (ko) * 2003-05-27 2007-10-25 포레스트 래보러토리즈, 인코포레이티드 우울증 및 그 밖의 기분장애의 치료를 위한 ｎｍｄａ수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물
US7432280B2 (en) * 2003-06-20 2008-10-07 Eli Lilly And Company 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake
WO2005067908A2 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer’s disease
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
JP2007529556A (ja) * 2004-03-19 2007-10-25 アクソニクス インコーポレイテッド 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤
FR2937119B1 (fr) 2008-10-15 2010-12-17 Air Liquide Procede de production d'energie et capture de co2
FR2937251B1 (fr) * 2008-10-16 2011-03-18 Servier Lab Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
FR2953515B1 (fr) * 2009-12-09 2011-12-23 Servier Lab Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
KR20130065602A (ko) 2013-06-19
CR20120608A (es) 2014-03-05
WO2013083887A1 (fr) 2013-06-13
US20130150421A1 (en) 2013-06-13
TN2012000563A1 (fr) 2014-04-01
UY34475A (es) 2013-07-31
MX2012014184A (es) 2013-06-18
FR2983732B1 (fr) 2013-11-22
CA2798549A1 (fr) 2013-06-09
EA201201530A1 (ru) 2013-07-30
BR102012031031A2 (pt) 2013-10-29
TW201334777A (zh) 2013-09-01
CN103157111B (zh) 2015-02-11
JP5591310B2 (ja) 2014-09-17
AR089112A1 (es) 2014-07-30
US20150080448A1 (en) 2015-03-19
GT201200329A (es) 2014-03-14
FR2983732A1 (fr) 2013-06-14
ECSP12012329A (es) 2013-01-31
WO2013083887A8 (fr) 2013-08-08
PE20130813A1 (es) 2013-07-28
EP2601942A1 (fr) 2013-06-12
CN103157111A (zh) 2013-06-19
TWI457123B (zh) 2014-10-21
NZ604084A (en) 2014-07-25
AP2012006607A0 (en) 2012-12-31
KR101489670B1 (ko) 2015-02-04
JP2013121956A (ja) 2013-06-20
NI201200178A (es) 2013-05-13
AU2012258339A1 (en) 2013-06-27
SG191494A1 (en) 2013-07-31
CO6660080A1 (es) 2013-04-30
MA34867B1 (fr) 2014-02-01
CO6690116A1 (es) 2013-06-17
CL2012003437A1 (es) 2014-01-24
US8921409B2 (en) 2014-12-30
MD4348B1 (ro) 2015-05-31

Similar Documents

Publication Publication Date Title
IL228506A (en) Opioid receptor ligands and pharmacy preparations containing them
HK1203191A1 (en) P2x4 receptor antagonist p2x4
HK1199259A1 (en) Lysophosphatidic acid receptor antagonists
HK1188211A1 (zh) 受體拮抗劑
EP2680697A4 (en) PROCESS FOR PREPARING AN OREXINE RECEPTOR ANTAGONIST
PL2552920T3 (pl) Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3
AP3104A (en) New association between 4-{3-[CIS-hexahydrocyclopenta[c]pyrrol-2(1H)-YL]propoxy}benzamide and an Acetylcholinesterase inhibitor, and pharmaceutical compositions containing it
EP2721011A4 (en) EP2 RECEPTOR ANTAGONISTS OF PROSTAGLANDINS, DERIVATIVES, COMPOSITIONS AND USES THEREOF
EP2619204A4 (en) TRIAZOLOPYRAZINONES AS ANTAGONISTS OF P2X7 RECEPTORS
HK1202867A1 (en) Substituted anilines as ccr(4) antagonists ccr(4)
EP2847343A4 (en) METHOD FOR PREPARING AN INTERMEDIATE FOR AN OREXIN RECEPTOR ANTAGONIST
EP2773352A4 (en) 1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONIST
HK1205104A1 (en) Novel neurokinin receptor antagonist compounds
EP2617717A4 (en) ANTAGONIST OF P2X4 RECEIVER
AP3225A (en) New combination between 4-{3-[CIS-hexahydrocyclopenta[C]pyrrol-2(1H)-yl]propoxy}benzamide and an NMDA receptor antagonist, and pharmaceutical compositions containing it
PT2935227T (pt) Amidas diazol como antagonistas do recetor ccr1
ZA201204183B (en) Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide hydrochloride and pharmaceutical compositions containing it
IL241743A0 (en) Non-competitive nicotinic receptor antagonists
EP2776054A4 (en) ANTAGONISTS FOR THE ORIGINAL VASOPRESSIN V2 RECEPTOR AND ITS USES
FR2976286B1 (fr) 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent
AU2012202328A1 (en) New Association Between 4-{3-[cis-Hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-propoxy}Benzamide and an Acetylcholinesterase inhibitor, and Pharmaceutical Compositions Containing It